Careers
Contact Us
Navigate Adaptimmune Limited
Home
Our Company
Overview
Board of Directors
Executive Committee
Partners
Scientific Advisory Board
Perspectives
Pipeline
Overview
ADP-A2M10 (MAGE-A10)
ADP-A2M4 (MAGE-A4)
ADP-A2AFP (AFP)
Technology
Overview
The Immune System
Our Engineered T-Cell Therapies
Our Technology Platform
Manufacturing
Intellectual Property
Publications
Patients & Families
Overview
Our Clinical Trials
Taking Part in our Clinical Trials
Clinical Trial FAQ
Cancer Information
Cancer Immunotherapy Month
Videos for Patients
News & Events
News
Scientific Conferences
Investor Conferences
Investors
You can find videos about our SPEAR T-cells for patients and their families
Learn More
Sharing our colleague’s perspectives on Women’s History Month
Click Here
Focusing on the needs of our patients
Learn More
Enhancing the Affinity of T-cell to Fight Cancer
Learn More
Investigating SPEAR T-Cell Therapy in 10 Solid Tumors
Learn More
Working with Leading Experts to Transform T-cell Therapy for Cancer Patients
Learn More
Latest News •
View all
April 18, 2019
Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
April 2, 2019
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
April 1, 2019
Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
Adaptimmune on Linkedin
Adaptimmune on Twitter
Tweets by Adaptimmune
Clinical Trials
Our Pipeline
Manufacturing
Partnerships
Perspectives
